POINTER: study protocol for a phase 2b, randomised, placebo-controlled, double-blind, parallel group dose-finding clinical study to evaluate the efficacy of RMC-035 on renal function and safety, in participants at high risk for kidney injury, following open-chest cardiac surgery | Trials

Explanation for the choice of comparators {6b}

The double-blind placebo-controlled design allows for an unbiased assessment of efficacy and safety. The use of placebo is justified by the intent to assess absolute efficacy and safety of RMC-035 and…

Continue Reading